Mechanism

How it works

HGH Fragment 176-191 mimics the action of the C-terminal region of native hGH on adipose tissue by activating beta-3 adrenergic receptors and stimulating hormone-sensitive lipase, promoting lipolysis. Unlike full-length hGH, it does not bind to the hGH receptor in a manner that triggers IGF-1 release or significant anabolic signaling, sparing users from hyperglycemia and growth-promoting side effects. It also inhibits lipogenesis by suppressing acetyl-CoA carboxylase activity, reducing the de novo synthesis of fatty acids.

Reported in research

Benefits

Promotes lipolysis (breakdown of stored body fat) without raising blood glucose or IGF-1 levels
Inhibits lipogenesis, reducing new fat cell formation particularly in visceral and subcutaneous depots
May support lean body mass preservation during caloric deficit phases
Potential bone density improvement observed in some preclinical studies

Context, not a prescription

Dosing

Typical range: 250–500 mcg/day, split into 1–2 injections (Subcutaneous)
Cycle length: 8–12 weeks
Half-life: ~30 minutes (short; some estimates up to 2 hours)

Safety

Side effects & contraindications

Possible side effects

Injection site redness, irritation, or mild swelling
Transient fatigue or lethargy reported by some users
Mild water retention in some cases
Occasional headache
Facial flushing immediately post-injection

Contraindications

Active malignancy or history of cancer (growth factor considerations)
Pregnancy or breastfeeding
Known hypersensitivity to hGH-derived peptides
Severe hepatic or renal impairment

Research information, not medical advice. Always consult a licensed clinician before considering any peptide.

In depth

Full profile

What it does

Gradual reduction in body fat, particularly around the abdomen and lower body. Skin may appear slightly firmer. Some users report slightly improved energy during workouts.

How it works

Think of human growth hormone as a Swiss Army knife with many tools. HGH Fragment 176-191 is like surgeons removing just the scissors (fat-burning tool) from that knife and using only those — so you get the cutting ability without accidentally deploying every other blade.

The peptide targets fat cells directly, flipping a switch that makes them release stored fat into the bloodstream where it can be burned for energy. At the same time, it signals fat cells not to store new fat. Because it does not trigger the full growth hormone pathway, blood sugar levels stay stable.

What to expect

Most users report subtle changes in body composition beginning around weeks 3–4, with more noticeable fat loss around week 6–8 when combined with a caloric deficit and regular exercise.

Week 1–2: Body is adjusting. You may notice mild injection site reactions. No visible fat loss yet; the peptide is establishing its signaling environment.
Weeks 3–6: Lipolytic effects begin to accumulate. Some users notice subtle tightening around the midsection, especially if in a mild caloric deficit.
Weeks 6–12: Peak period for visible body composition changes. Fat loss is most apparent when combined with diet and training. Some users report improved definition and energy.

Good to know

Rotate injection sites to avoid tissue irritation
Start at the lower end of the dose (250 mcg/day) to assess tolerance
Inject on an empty stomach or at least 30 minutes before a meal for best results
Keep reconstituted peptide refrigerated and use within 30 days

Staying safe

Redness or mild soreness at the injection spot
Occasional tiredness shortly after injection
Mild water retention early in the cycle

Avoid if you have:

People with a history of cancer
Pregnant or breastfeeding individuals
People with known allergies to growth hormone peptides

Overview

Progressive reduction in adipose tissue mass, particularly in visceral depots. No significant alterations in fasting insulin, IGF-1, IGFBP-3, or glucose tolerance have been documented in clinical or preclinical research. Some preclinical studies noted improvements in trabecular bone mineral density, potentially through a secondary mechanism involving lipid metabolism in bone marrow adipocytes.

How it works

Native hGH is a multi-domain ligand that engages its receptor like a two-handed handshake (site 1 and site 2 binding interfaces) to trigger receptor dimerization and JAK2 activation. Fragment 176-191 operates like someone who can only shake with one hand — it can engage the adipocyte beta-3 receptor to trigger lipolysis but cannot complete the structural handshake needed to dimerize the GHR and initiate IGF-1 signaling.

Following subcutaneous administration, the peptide is rapidly absorbed with a short half-life estimated at 30–120 minutes due to proteolytic degradation. It distributes primarily to adipose tissue. Pharmacodynamically, the primary effect is on visceral and subcutaneous adipose depots through the beta-3 AR/cAMP/PKA/HSL axis. Studies in obese Zucker rats and murine models demonstrated significant reductions in total body fat mass without changes in food intake, IGF-1 levels, or lean body mass. Limited Phase II clinical trials (AOD9604) in obese human subjects showed modest but statistically significant reductions in body weight over 12-week periods at doses of 1 mg/day, though results were not replicated sufficiently for regulatory approval.

Onset & timeline

Pharmacodynamic lipolytic effects are detectable within hours of a single dose in in vitro and animal models. In humans, clinical body composition changes typically require 4–8 weeks of consistent administration given the relatively small per-dose effect on fat mass and the gradual nature of adipose remodeling.

Days 1–7: Peptide establishes steady-state tissue exposure with repeated dosing. Acute lipolytic signaling is occurring at the cellular level, but body composition changes are not yet measurable. Minor injection site reactions may be present.
Weeks 2–4: Accumulating lipolytic signaling begins to produce measurable reductions in adipose tissue. Subjects in caloric deficit may notice accelerated fat loss. HSL phosphorylation state in adipocytes is chronically elevated.
Weeks 4–12: Peak morphological changes become visible. In animal studies, body fat percentage reductions of 50% vs. controls were observed by week 8. Human data shows more modest effects (1–2 kg fat reduction over 12 weeks in clinical trials). Lean body mass is preserved.

Getting the most from it

Use bacteriostatic water for reconstitution and adhere to sterile injection technique to minimize infection risk
Administer in a fasted state to optimize beta-3 AR sensitivity and minimize insulin-mediated antagonism of lipolysis
Systematic rotation of injection sites across abdomen, thigh, and deltoid regions to prevent lipodystrophy
Baseline and follow-up measurement of fasting glucose, IGF-1, and lipid panel to monitor metabolic response

Common side effects

Injection site erythema and induration (most common; typically resolves within 24–48 hours)
Transient hypotension or lightheadedness immediately post-injection attributed to vasodilatory cAMP effects
Mild fatigue in the first 1–2 weeks of use

Mechanism of action

HGH Fragment 176-191 corresponds to the C-terminal helical region of native hGH. It activates beta-3 adrenergic receptors on adipocytes, stimulating adenylyl cyclase and elevating intracellular cAMP, which in turn activates protein kinase A (PKA) and subsequently hormone-sensitive lipase (HSL) via phosphorylation. HSL then hydrolyzes triglycerides stored in adipocyte lipid droplets into free fatty acids and glycerol. Concurrently, the fragment inhibits acetyl-CoA carboxylase (ACC), the rate-limiting enzyme of de novo lipogenesis, reducing fatty acid synthesis. Because the fragment lacks the extracellular domain interaction required for full GHR dimerization, it does not activate the canonical JAK2/STAT5 signaling cascade, meaning IGF-1 secretion and anabolic gene transcription remain unaffected.

Following subcutaneous administration, the peptide is rapidly absorbed with a short half-life estimated at 30–120 minutes due to proteolytic degradation. It distributes primarily to adipose tissue. Pharmacodynamically, the primary effect is on visceral and subcutaneous adipose depots through the beta-3 AR/cAMP/PKA/HSL axis. Studies in obese Zucker rats and murine models demonstrated significant reductions in total body fat mass without changes in food intake, IGF-1 levels, or lean body mass. Limited Phase II clinical trials (AOD9604) in obese human subjects showed modest but statistically significant reductions in body weight over 12-week periods at doses of 1 mg/day, though results were not replicated sufficiently for regulatory approval.

Pharmacodynamics

Pharmacodynamic lipolytic effects are detectable within hours of a single dose in in vitro and animal models. In humans, clinical body composition changes typically require 4–8 weeks of consistent administration given the relatively small per-dose effect on fat mass and the gradual nature of adipose remodeling.

Progressive reduction in adipose tissue mass, particularly in visceral depots. No significant alterations in fasting insulin, IGF-1, IGFBP-3, or glucose tolerance have been documented in clinical or preclinical research. Some preclinical studies noted improvements in trabecular bone mineral density, potentially through a secondary mechanism involving lipid metabolism in bone marrow adipocytes.

Timeline

Days 1–7: Peptide establishes steady-state tissue exposure with repeated dosing. Acute lipolytic signaling is occurring at the cellular level, but body composition changes are not yet measurable. Minor injection site reactions may be present.
Weeks 2–4: Accumulating lipolytic signaling begins to produce measurable reductions in adipose tissue. Subjects in caloric deficit may notice accelerated fat loss. HSL phosphorylation state in adipocytes is chronically elevated.
Weeks 4–12: Peak morphological changes become visible. In animal studies, body fat percentage reductions of 50% vs. controls were observed by week 8. Human data shows more modest effects (1–2 kg fat reduction over 12 weeks in clinical trials). Lean body mass is preserved.

Comparisons

HGH Fragment 176-191 — effectiveness Moderate, safety Good, cost $$, Medium to use
Tesamorelin (GHRH analog) — effectiveness High, safety Good, cost $$$$, Medium to use
Full-length recombinant hGH — effectiveness Very High, safety Moderate, cost $$$$, Low to use

Adverse effects

Common:

Injection site erythema and induration (most common; typically resolves within 24–48 hours)
Transient hypotension or lightheadedness immediately post-injection attributed to vasodilatory cAMP effects
Mild fatigue in the first 1–2 weeks of use

Rare:

Systemic allergic reaction (very rare; incidence not formally quantified in human trials)
Persistent injection site lipodystrophy with chronic use at the same site

Contraindications & risk mitigation

Contraindicated in:

Individuals with active or history of hormone-sensitive malignancies
Patients on insulin or hypoglycemic agents (monitor glycemic indices)
Individuals with known beta-adrenergic hypersensitivity
Patients with severe renal or hepatic dysfunction affecting peptide clearance

Use bacteriostatic water for reconstitution and adhere to sterile injection technique to minimize infection risk
Administer in a fasted state to optimize beta-3 AR sensitivity and minimize insulin-mediated antagonism of lipolysis
Systematic rotation of injection sites across abdomen, thigh, and deltoid regions to prevent lipodystrophy
Baseline and follow-up measurement of fasting glucose, IGF-1, and lipid panel to monitor metabolic response

Qué hace

Gradual reduction in body fat, particularly around the abdomen and lower body. Skin may appear slightly firmer. Some users report slightly improved energy during workouts.

Cómo funciona

Think of human growth hormone as a Swiss Army knife with many tools. HGH Fragment 176-191 is like surgeons removing just the scissors (fat-burning tool) from that knife and using only those — so you get the cutting ability without accidentally deploying every other blade.

The peptide targets fat cells directly, flipping a switch that makes them release stored fat into the bloodstream where it can be burned for energy. At the same time, it signals fat cells not to store new fat. Because it does not trigger the full growth hormone pathway, blood sugar levels stay stable.

Qué esperar

Most users report subtle changes in body composition beginning around weeks 3–4, with more noticeable fat loss around week 6–8 when combined with a caloric deficit and regular exercise.

Week 1–2: Body is adjusting. You may notice mild injection site reactions. No visible fat loss yet; the peptide is establishing its signaling environment.
Weeks 3–6: Lipolytic effects begin to accumulate. Some users notice subtle tightening around the midsection, especially if in a mild caloric deficit.
Weeks 6–12: Peak period for visible body composition changes. Fat loss is most apparent when combined with diet and training. Some users report improved definition and energy.

Bueno saber

Rotate injection sites to avoid tissue irritation
Start at the lower end of the dose (250 mcg/day) to assess tolerance
Inject on an empty stomach or at least 30 minutes before a meal for best results
Keep reconstituted peptide refrigerated and use within 30 days

Manteniéndose seguro

Redness or mild soreness at the injection spot
Occasional tiredness shortly after injection
Mild water retention early in the cycle

Evitar si tienes:

People with a history of cancer
Pregnant or breastfeeding individuals
People with known allergies to growth hormone peptides

Descripción general

Progressive reduction in adipose tissue mass, particularly in visceral depots. No significant alterations in fasting insulin, IGF-1, IGFBP-3, or glucose tolerance have been documented in clinical or preclinical research. Some preclinical studies noted improvements in trabecular bone mineral density, potentially through a secondary mechanism involving lipid metabolism in bone marrow adipocytes.

Cómo funciona

Native hGH is a multi-domain ligand that engages its receptor like a two-handed handshake (site 1 and site 2 binding interfaces) to trigger receptor dimerization and JAK2 activation. Fragment 176-191 operates like someone who can only shake with one hand — it can engage the adipocyte beta-3 receptor to trigger lipolysis but cannot complete the structural handshake needed to dimerize the GHR and initiate IGF-1 signaling.

Following subcutaneous administration, the peptide is rapidly absorbed with a short half-life estimated at 30–120 minutes due to proteolytic degradation. It distributes primarily to adipose tissue. Pharmacodynamically, the primary effect is on visceral and subcutaneous adipose depots through the beta-3 AR/cAMP/PKA/HSL axis. Studies in obese Zucker rats and murine models demonstrated significant reductions in total body fat mass without changes in food intake, IGF-1 levels, or lean body mass. Limited Phase II clinical trials (AOD9604) in obese human subjects showed modest but statistically significant reductions in body weight over 12-week periods at doses of 1 mg/day, though results were not replicated sufficiently for regulatory approval.

Inicio y cronología

Pharmacodynamic lipolytic effects are detectable within hours of a single dose in in vitro and animal models. In humans, clinical body composition changes typically require 4–8 weeks of consistent administration given the relatively small per-dose effect on fat mass and the gradual nature of adipose remodeling.

Days 1–7: Peptide establishes steady-state tissue exposure with repeated dosing. Acute lipolytic signaling is occurring at the cellular level, but body composition changes are not yet measurable. Minor injection site reactions may be present.
Weeks 2–4: Accumulating lipolytic signaling begins to produce measurable reductions in adipose tissue. Subjects in caloric deficit may notice accelerated fat loss. HSL phosphorylation state in adipocytes is chronically elevated.
Weeks 4–12: Peak morphological changes become visible. In animal studies, body fat percentage reductions of 50% vs. controls were observed by week 8. Human data shows more modest effects (1–2 kg fat reduction over 12 weeks in clinical trials). Lean body mass is preserved.

Cómo aprovecharlo al máximo

Use bacteriostatic water for reconstitution and adhere to sterile injection technique to minimize infection risk
Administer in a fasted state to optimize beta-3 AR sensitivity and minimize insulin-mediated antagonism of lipolysis
Systematic rotation of injection sites across abdomen, thigh, and deltoid regions to prevent lipodystrophy
Baseline and follow-up measurement of fasting glucose, IGF-1, and lipid panel to monitor metabolic response

Efectos secundarios comunes

Injection site erythema and induration (most common; typically resolves within 24–48 hours)
Transient hypotension or lightheadedness immediately post-injection attributed to vasodilatory cAMP effects
Mild fatigue in the first 1–2 weeks of use

Mecanismo de acción

HGH Fragment 176-191 corresponds to the C-terminal helical region of native hGH. It activates beta-3 adrenergic receptors on adipocytes, stimulating adenylyl cyclase and elevating intracellular cAMP, which in turn activates protein kinase A (PKA) and subsequently hormone-sensitive lipase (HSL) via phosphorylation. HSL then hydrolyzes triglycerides stored in adipocyte lipid droplets into free fatty acids and glycerol. Concurrently, the fragment inhibits acetyl-CoA carboxylase (ACC), the rate-limiting enzyme of de novo lipogenesis, reducing fatty acid synthesis. Because the fragment lacks the extracellular domain interaction required for full GHR dimerization, it does not activate the canonical JAK2/STAT5 signaling cascade, meaning IGF-1 secretion and anabolic gene transcription remain unaffected.

Following subcutaneous administration, the peptide is rapidly absorbed with a short half-life estimated at 30–120 minutes due to proteolytic degradation. It distributes primarily to adipose tissue. Pharmacodynamically, the primary effect is on visceral and subcutaneous adipose depots through the beta-3 AR/cAMP/PKA/HSL axis. Studies in obese Zucker rats and murine models demonstrated significant reductions in total body fat mass without changes in food intake, IGF-1 levels, or lean body mass. Limited Phase II clinical trials (AOD9604) in obese human subjects showed modest but statistically significant reductions in body weight over 12-week periods at doses of 1 mg/day, though results were not replicated sufficiently for regulatory approval.

Farmacodinamia

Pharmacodynamic lipolytic effects are detectable within hours of a single dose in in vitro and animal models. In humans, clinical body composition changes typically require 4–8 weeks of consistent administration given the relatively small per-dose effect on fat mass and the gradual nature of adipose remodeling.

Progressive reduction in adipose tissue mass, particularly in visceral depots. No significant alterations in fasting insulin, IGF-1, IGFBP-3, or glucose tolerance have been documented in clinical or preclinical research. Some preclinical studies noted improvements in trabecular bone mineral density, potentially through a secondary mechanism involving lipid metabolism in bone marrow adipocytes.

Cronología

Days 1–7: Peptide establishes steady-state tissue exposure with repeated dosing. Acute lipolytic signaling is occurring at the cellular level, but body composition changes are not yet measurable. Minor injection site reactions may be present.
Weeks 2–4: Accumulating lipolytic signaling begins to produce measurable reductions in adipose tissue. Subjects in caloric deficit may notice accelerated fat loss. HSL phosphorylation state in adipocytes is chronically elevated.
Weeks 4–12: Peak morphological changes become visible. In animal studies, body fat percentage reductions of 50% vs. controls were observed by week 8. Human data shows more modest effects (1–2 kg fat reduction over 12 weeks in clinical trials). Lean body mass is preserved.

Comparaciones

HGH Fragment 176-191 — efectividad Moderate, seguridad Good, costo $$, Medium de usar
Tesamorelin (GHRH analog) — efectividad High, seguridad Good, costo $$$$, Medium de usar
Full-length recombinant hGH — efectividad Very High, seguridad Moderate, costo $$$$, Low de usar

Efectos adversos

Comunes:

Injection site erythema and induration (most common; typically resolves within 24–48 hours)
Transient hypotension or lightheadedness immediately post-injection attributed to vasodilatory cAMP effects
Mild fatigue in the first 1–2 weeks of use

Raros:

Systemic allergic reaction (very rare; incidence not formally quantified in human trials)
Persistent injection site lipodystrophy with chronic use at the same site

Contraindicaciones y mitigación de riesgos

Contraindicado en:

Individuals with active or history of hormone-sensitive malignancies
Patients on insulin or hypoglycemic agents (monitor glycemic indices)
Individuals with known beta-adrenergic hypersensitivity
Patients with severe renal or hepatic dysfunction affecting peptide clearance

Use bacteriostatic water for reconstitution and adhere to sterile injection technique to minimize infection risk
Administer in a fasted state to optimize beta-3 AR sensitivity and minimize insulin-mediated antagonism of lipolysis
Systematic rotation of injection sites across abdomen, thigh, and deltoid regions to prevent lipodystrophy
Baseline and follow-up measurement of fasting glucose, IGF-1, and lipid panel to monitor metabolic response

Reference data

Specifications

Molecular formula: C78H125N23O23S2
Molecular weight: 1817.12 g/mol
Half-life: ~30 minutes (short; some estimates up to 2 hours)
Route: Subcutaneous
Cycle length: 8–12 weeks
Storage: Store lyophilized powder at 2–8°C (refrigerated); protect from light. Once reconstituted with bacteriostatic water, store at 2–8°C and use within 28–30 days. Do not freeze reconstituted solution.
Legal status: Research chemical; not approved by the FDA or most regulatory bodies for therapeutic use in humans. Banned in sport by WADA. Regulatory status varies by country.

FAQ

Common questions

How does HGH Fragment 176-191 differ mechanistically from AOD-9604?

AOD-9604 is essentially the clinical/pharmaceutical designation for the same amino acid sequence (hGH 176-191) with a tyrosine added at the N-terminus to facilitate radiolabeling in early pharmacokinetic studies. For research purposes, the two terms are often used interchangeably, though AOD-9604 specifically refers to the Metabolic Pharmaceuticals formulation studied in obesity clinical trials.

Does combining HGH Fragment 176-191 with a GHRH or GHRP offer synergistic fat loss?

Theoretically yes. Stacking with a GHRH analog (e.g., CJC-1295 or Mod-GRF 1-29) increases endogenous GH pulsatility, which can further potentiate lipolytic signaling through full-length GH pathways. However, this introduces the metabolic effects of full GH secretion (including IGF-1 elevation and potential insulin resistance), partially offsetting the metabolic selectivity advantage of Fragment 176-191 alone. No controlled human trials have evaluated this combination.

What is the evidence level?

This compound is classified as Limited human data. Some human data exists but trials are small, short-term, or not yet replicated.

Research

Research & sources

Limited human

Current evidence for HGH Fragment 176-191 is rated as Limited human data. Limited human data is available.

1. Lipolytic action of a fragment of human growth hormone spanning amino acids 176-191 (1996) — Biochemical and Biophysical Research Communications, 220(3):751-755
2. AOD9604: An Anti-Obesity Drug with Some Insulin Sensitizing Activities in Zucker Rats (2006) — Obesity Facts, Karger, DOI: 10.1159/000094904
3. The lipolytic effect of a growth hormone fragment with sequence 177-191 (1994) — Biochemistry, 33(16):4845-4851
4. Phase II randomized controlled trial of AOD9604 in obese subjects (2001) — Growth Hormone & IGF Research, Elsevier

Explore

Often discussed alongside

CJC-1295 · growth Ipamorelin · growth BPC-157 · healing Tesamorelin · fat-loss